Prostate Cancer Treatment: What is the New HIFU?

0
(0)

The U.S. Food and Drug Administration (FDA) has recently approved a new non-surgical treatment option for patients with prostate cancer. The non-invasive method is called High-Intensity Focused Ultrasound (HIFU) therapy and Dr. David Samadi explains more about in the video above.

HIFU is used to destroy diseased prostate tissue without harming the surrounding tissue and was approved by the FDA after 10 years of use Europe and Canada.

“For selected patients with low-risk prostate cancer and a small prostate, this can actually play a role. There is a transducer in the rectum, and with a general anesthesia, you basically use a high focus ultrasound energy and you can actually burn the cancer cells,” said Samadi in the video.

Dr. Samadi said data from HIFU in Europe shows effective results among selected prostate cancer patients.

HIFU is meant for low-risk patients in stage T-1 or T-2 of prostate cancer confined to the gland.  The treatment consists of ultrasound waves precisely directed at the tumor via a computer controlled rectal probe to destroy the prostate cancer cells. The process can be repeated if necessary. Although side effects are lower than from surgery or radiation, HIFU may cause incontinence or erectile dysfunction.

Maple Leaf HIFU is the first provider of this technology and treatment in North America.

Read more about High-Intensity Focused Ultrasound (HIFU): http://bit.ly/2260QZa

Learn more about prostate cancer.

Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • NCCN and Rubraca
  • Orgovyx and FDA approval
  • Lynparza
  • Erleada results

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *